ArticleCureus2025
A Case of Corneal Endothelial Cell Loss After PreserFlo MicroShunt Implantation Requiring Device Removal and Ahmed Glaucoma Valve Implantation With Tube Insertion Into the Vitreous Cavity.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of progressive endothelial cell loss (ECL) following PreserFlo MicroShunt (PMS) (Santen Pharmaceutical, Osaka, Japan) implantation, which was successfully managed by PMS removal and the pars plana placement of Ahmed glaucoma valve (AGV) implantation. An 82-year-old man with primary open-angle glaucoma underwent PMS implantation combined with cataract surgery. Preoperative endothelial cell density (ECD) was 2,148 cells/mm², and intraocular pressure (IOP) was 21 mmHg despite five topical IOP-lowering medications. One week postoperatively, the IOP normalized to 11 mmHg without medication, but the ECD decreased to 1,400 cells/mm². Over the following 12 months, the ECD progressively declined to 880 cells/mm². PMS removal and AGV implantation, with tube insertion into the vitreous cavity, were performed to prevent further ECL and maintain IOP control. After the second surgery, IOP stabilized between 10 and 14 mmHg with topical treatment, including ripasudil, and ECD remained stable at approximately 1,200 cells/mm². This case demonstrates the potential for significant and progressive ECL following PMS implantation and highlights that timely intervention with PMS removal and AGV implantation with tube insertion into the vitreous cavity can effectively stabilize ECD and achieve adequate IOP control, emphasizing the importance of close postoperative monitoring and the prompt management of complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.